Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Otilimab - GlaxoSmithKline

Drug Profile

Otilimab - GlaxoSmithKline

Alternative Names: GSK-3196165; GSK165; MOR-103

Latest Information Update: 26 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer GlaxoSmithKline; MorphoSys
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • No development reported Inflammation
  • Discontinued Multiple sclerosis; Osteoarthritis

Most Recent Events

  • 12 Jun 2019 Efficacy data from a phase IIb trial in Rheumatoid arthritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
  • 04 Jun 2019 GlaxoSmithKline initiates enrolment in a phase III trial for Rheumatoid arthritis in the USA (SC)(NCT03970837)
  • 03 Jun 2019 GlaxoSmithKline plans a phase III trial for Rheumatoid arthritis (Treatment experienced) in USA (NCT03970837)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top